SISRAM MED (01696) Reports Double-Digit YoY Growth in Unaudited Q3 Revenue, Advances Commercialization of DaxiFacial in Mainland China
Stock News
Oct 28
SISRAM MED (01696) announced that the group maintained strong growth momentum in new orders during the third quarter of 2025, driven primarily by performance in China, South Korea, and Thailand markets. Its multifunctional flagship device, Alma Harmony, achieved steady growth this quarter. As a result, the group reported unaudited double-digit year-on-year revenue growth for the period.
Leveraging continuous market expansion and demand exploration, the group will further enhance the penetration of its Soprano series in the Asia-Pacific region this year and fully advance the commercial deployment of Universkin by Alma in the U.S. market. Meanwhile, it will proceed as planned with the orderly commercialization of DaxiFacial in Mainland China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.